Neurocrine Bio. (NBIX) and TAK Collaboration Could Be Transformative - Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $134.00 price target on Neurocrine Bio. (NASDAQ: NBIX), citing a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
